Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Scientists discover a novel strategy to unmask cancer cells in high-risk neuroblastoma

High-risk neuroblastoma is one of the most aggressive forms of solid tumors affecting children, originating in the nervous system.

6 Oct 2026

Label-free microfluidic chip and AI identify blood-borne tumor cells

Finding a few tumor cells hidden among billions of blood cells is one of the biggest challenges in liquid biopsy.

30 Sep 2026

Pneumococcal disease may signal undiagnosed blood cancer

Severe pneumococcal disease requiring hospitalization, most commonly pneumonia, can be a sign of previously undiagnosed blood cancer and immunodeficiency in adult patients, according to a study from the University of Gothenburg.

30 Sep 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

AtlasPlex™ brings custom 5-plex IHC on FFPE tissue into a single day

Atlas Antibodies has launched AtlasPlex™, a new ready-to-use multiplex immunohistochemistry kit. It lets researchers build their own 3- or 5-plex panels from more than 17,000 IHC-validated antibodies covering over 12,000 human genes.

From Atlas Antibodies AB 30 Sep 2026

Atlas Antibodies marks 20 years of Human Protein Atlas–validated antibodies

Atlas Antibodies is 20 years old. The company is the original manufacturer of the antibodies used to map the human proteome in the Human Protein Atlas (HPA).

From Atlas Antibodies AB 30 Sep 2026

MolBoolean™ measures free and bound proteins in the same experiment

Atlas Antibodies has launched MolBoolean™, a new in situ proximity assay. It detects free protein A, free protein B, and the A–B complex together in fixed cells and tissue.

From Atlas Antibodies AB 30 Sep 2026

New study explains how TMEM63B protein regulates cell membranes

An autoinhibitory domain in the C-terminal tail of the TMEM63B, a mechanosensitive lipid scramblase, helps maintain its inactive state under resting conditions, report researchers from Institute of Science Tokyo.

29 Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

New antibody treatment blocks immune response to prevent Alzheimer's damage

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer's disease, in which twisted clumps of a protein called tau accumulate in the brain.

28 Sep 2026

Laser irradiation boosts antibody-antigen interactions to detect colorectal cancer

Researchers often use antibodies to detect specific molecules or biological markers, as they are remarkably precise at recognizing their targets.

25 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.

24 Sep 2026